1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €25.89 (+172.81%). The median is €25.89 (+172.81%).
| Buy |
7 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -4.21M | 161.98% |
| EBITDA | -3.92M | 150.60% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €10.57M |
Number of shares | 1.14M |
52-week high/low | €42.81 - €2.60 |
| Dividends | No |
Beta | 1.39 |
P/E ratio | -0.01 |
PEG ratio | 0.00 |
P/B ratio | 1.03 |
P/S ratio | 0.00 |
Company profile
| Name | Akari Therapeutics ADR |
| CEO | Abizer Gaslightwala |
| Employees | 6 |
Discover assets
Shareholders of Akari Therapeutics ADR also invest in the following assets
